Tevogen Bio shares jump 21.90% premarket after reporting major clinical milestone expanding HLA coverage for T cell therapy.

Tevogen Bio Holdings surged 21.90% in premarket trading following the announcement of a major clinical milestone: the identification of five additional human leukocyte antigen (HLA) targets for its precision T cell therapy platform. This expansion increases the potential patient pool from 25% to 65% of the U.S. population, significantly broadening accessibility for minority groups with less common HLA types. The advancement follows a successful proof-of-concept trial demonstrating safety and feasibility in high-risk COVID-19 patients, reinforcing the company’s progress in developing scalable, third-party cytotoxic T lymphocyte therapies. The news underscores Tevogen’s strategic shift toward more inclusive treatment options, likely driving investor optimism about commercialization potential and market reach.